Oral Immunotherapy for Wheat Allergy

Inclusion Criteria: * Age 4-30 years either sex, any race, any ethnicity * Positive Prick Skin Test to wheat greater than 3mm compared to control and/or a wheat specific IgE \>= 0.35 kUA/L * Positive baseline challenge to wheat (\<= 1923 mg of vital wheat gluten) * Written informed consent from subject and/or parent/guardian * Written assent from all subjects as appropriate * All females of child bearing age must be using appropriate birth control Exclusion Criteria: * History of anaphylaxis to wheat resulting in hypotension, neurological compromise or mechanical ventilation * Known allergy to corn * Known celiac disease * Chronic disease (other than asthma, atopic dermatitis, rhinitis) requiring therapy (e.g., heart disease, diabetes) * Active eosinophilic gastrointestinal disease in the past two years * Participation in any interventional study for the treatment of food allergy in the past 6 months * Subject is on "build-up phase" of immunotherapy (i.e., has not reached maintenance dosing). Subjects tolerating maintenance allergen immunotherapy can be enrolled. * Severe asthma, uncontrolled mild or moderate asthma. More information on this criterion can be found in the protocol. * A burst of oral, IM or IV steroids of more than 2 days for an indication other than asthma in the past 1 month * Inability to discontinue antihistamines for initial day escalation, skin testing or OFC * Use of omalizumab or other non-traditional forms of allergen immunotherapy or immunomodulator therapy (not including corticosteroids) or biologic therapy within the past year * Use of beta-blockers (oral), angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARB) or calcium channel blockers * Use of investigational drug within 90 days or plan to use investigational drug during the study period * Pregnancy or lactation